Full Year 2025 loss at CytomX Therapeutics, Inc. (CTMX) was $0.15 per share GAAP. Revenue of $76.2M was reported for the full year.
Year-over-year, EPS moved down 139.5% from the $0.38 posted in Full Year 2024. That represents a 44.8% decline from the $138.1M recorded in Full Year 2024
A detailed analysis of CytomX Therapeutics, Inc.’s quarter follows shortly on AlphaStreet.
This article was generated using AlphaStreet’s proprietary financial analysis technology and reviewed by our editorial team.